Drugs / RHH646
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05816395 | May 2023 → Feb 2025 | osteoarthritis, knee | Novartis Pharmaceuticals | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RHH646 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05816395 ↗ |
| Route | Oral | “RHH646 was administered orally once per day for a year.” NCT05816395 ↗ |